RxDoctor Payments Data

Rushickah Brooks, APRN

Family · Hartford, CTNPI 1093267981

Payments from drug & device makers

$1,615in general payments, 2019–2025

Across 48 payments — averaging $33.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$573
  • Lilly USA, LLC$221
  • Tandem Diabetes Care, Inc.$152
  • Xeris Pharmaceuticals, Inc.$139
  • Bayer$121
  • Novo Nordisk$100
  • plus $308 from 9 others

What the payments were for

  • Food & beverage$1,615100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,615 in reported general payments places this provider in the 75th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$16,782
Medicare patients
43
Services billed
208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide97$104,957
MounjaroTirzepatide78$91,579
JardianceEmpagliflozin52$75,250
TrulicityDulaglutide52$63,614
FarxigaDapagliflozin Propanediol31$33,491
JanuviaSitagliptin Phosphate33$32,095
Tresiba Flextouch U-200Insulin Degludec21$28,270
Tresiba Flextouch U-100Insulin Degludec30$21,963
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$18,103
Lantus SolostarInsulin Glargine,hum.Rec.Anlog98$15,313
Humalog Kwikpen U-100Insulin Lispro60$13,894
TradjentaLinagliptin12$11,346
JentaduetoLinagliptin/Metformin Hcl16$8,738
Novolog FlexpenInsulin Aspart27$5,345
Insulin Lispro Kwikpen U-100Insulin Lispro22$5,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$221$156,984142 claims
Novo NordiskOzempic$100$104,95797 claims
AstraZenecaFarxiga$26$33,49131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,596 family providers in Connecticut.

Other family in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →